{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "20",
                "@timestamp": "2023-07-20T13:54:45.000045-04:00",
                "@year": "2023",
                "@month": "07"
            },
            "ait:date-sort": {
                "@day": "16",
                "@year": "2023",
                "@month": "02"
            }
        },
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60007651",
                            "@country": "usa",
                            "city": "Bethesda",
                            "organization": [
                                {"$": "National Eye Institute"},
                                {"$": "National Institutes of Health"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60007651"},
                                {"@afid": "60006577"}
                            ],
                            "state": "MD",
                            "ce:source-text": "National Eye Institute, National Institutes of Health, Bethesda, Maryland"
                        },
                        "author": [
                            {
                                "ce:given-name": "Sunil",
                                "preferred-name": {
                                    "ce:given-name": "Sunil",
                                    "ce:initials": "S.",
                                    "ce:surname": "Bellur",
                                    "ce:indexed-name": "Bellur S."
                                },
                                "@seq": "1",
                                "ce:initials": "S.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Bellur",
                                "@auid": "57471254100",
                                "ce:indexed-name": "Bellur S."
                            },
                            {
                                "ce:given-name": "Matthew",
                                "preferred-name": {
                                    "ce:given-name": "Matthew",
                                    "ce:initials": "M.",
                                    "ce:surname": "McHarg",
                                    "ce:indexed-name": "McHarg M."
                                },
                                "@seq": "2",
                                "ce:initials": "M.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "BS",
                                "ce:surname": "McHarg",
                                "@auid": "57216320606",
                                "ce:indexed-name": "McHarg M."
                            },
                            {
                                "ce:given-name": "Wijak",
                                "preferred-name": {
                                    "ce:given-name": "Wijak",
                                    "ce:initials": "W.",
                                    "ce:surname": "Kongwattananon",
                                    "ce:indexed-name": "Kongwattananon W."
                                },
                                "@seq": "3",
                                "ce:initials": "W.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Kongwattananon",
                                "@auid": "57194411173",
                                "ce:indexed-name": "Kongwattananon W."
                            },
                            {
                                "ce:given-name": "Susan",
                                "preferred-name": {
                                    "ce:given-name": "Susan",
                                    "ce:initials": "S.",
                                    "ce:surname": "Vitale",
                                    "ce:indexed-name": "Vitale S."
                                },
                                "@seq": "4",
                                "ce:initials": "S.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "PhD",
                                "ce:surname": "Vitale",
                                "@auid": "7102690268",
                                "ce:indexed-name": "Vitale S."
                            },
                            {
                                "ce:given-name": "H. Nida",
                                "preferred-name": {
                                    "ce:given-name": "H. Nida",
                                    "ce:initials": "H.N.",
                                    "ce:surname": "Sen",
                                    "ce:indexed-name": "Sen H.N."
                                },
                                "@seq": "5",
                                "ce:initials": "H.N.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Sen",
                                "@auid": "7003412064",
                                "ce:indexed-name": "Sen H.N."
                            },
                            {
                                "ce:given-name": "Shilpa",
                                "preferred-name": {
                                    "ce:given-name": "Shilpa",
                                    "ce:initials": "S.",
                                    "ce:surname": "Kodati",
                                    "ce:indexed-name": "Kodati S."
                                },
                                "@seq": "6",
                                "ce:initials": "S.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Kodati",
                                "@auid": "57192708531",
                                "ce:indexed-name": "Kodati S."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60025286",
                            "@country": "usa",
                            "city": "Washington",
                            "organization": [
                                {"$": "George Washington University"},
                                {"$": "School of Medicine and Health Sciences"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60025286"},
                                {"@afid": "60003088"}
                            ],
                            "state": "DC",
                            "ce:source-text": "George Washington University School of Medicine and Health Sciences, Washington, DC"
                        },
                        "author": [
                            {
                                "ce:given-name": "Matthew",
                                "preferred-name": {
                                    "ce:given-name": "Matthew",
                                    "ce:initials": "M.",
                                    "ce:surname": "McHarg",
                                    "ce:indexed-name": "McHarg M."
                                },
                                "@seq": "2",
                                "ce:initials": "M.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "BS",
                                "ce:surname": "McHarg",
                                "@auid": "57216320606",
                                "ce:indexed-name": "McHarg M."
                            },
                            {
                                "ce:given-name": "H. Nida",
                                "preferred-name": {
                                    "ce:given-name": "H. Nida",
                                    "ce:initials": "H.N.",
                                    "ce:surname": "Sen",
                                    "ce:indexed-name": "Sen H.N."
                                },
                                "@seq": "5",
                                "ce:initials": "H.N.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Sen",
                                "@auid": "7003412064",
                                "ce:indexed-name": "Sen H.N."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60022183",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Chulalongkorn University"},
                                {"$": "King Chulalongkorn Memorial Hospital"},
                                {"$": "Thai Red Cross Society"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60022183"},
                                {"@afid": "60031780"},
                                {"@afid": "60028190"}
                            ],
                            "ce:source-text": "Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Wijak",
                            "preferred-name": {
                                "ce:given-name": "Wijak",
                                "ce:initials": "W.",
                                "ce:surname": "Kongwattananon",
                                "ce:indexed-name": "Kongwattananon W."
                            },
                            "@seq": "3",
                            "ce:initials": "W.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Kongwattananon",
                            "@auid": "57194411173",
                            "ce:indexed-name": "Kongwattananon W."
                        }]
                    }
                ],
                "citation-title": "Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients with Noninfectious Uveitis",
                "abstracts": "© 2023 American Medical Association. All rights reserved.Importance: Tumor necrosis factor inhibitors (TNFis) can induce antidrug antibody (ADA) formation and loss of therapeutic response. However, the utility of ADA testing and the association between ADAs and treatment response in patients with noninfectious uveitis (NIU) is not well understood. Objective: To assess the frequency of ADAs and their association with drug levels and clinical response in patients with NIU treated with adalimumab or infliximab. Design, Setting, and Participants: This retrospective cross-sectional study included patients diagnosed with NIU who received adalimumab or infliximab and underwent testing for serum drug level and ADAs at the National Eye Institute from September 2017 to July 2021. Exposures: Serum drug level testing with reflex testing for ADA levels was performed. Main Outcomes and Measures: The main outcome was the association between drug levels and ADAs, clinical response, and concurrent antimetabolite use in patients treated with TNFis for NIU. Results: Of 54 patients included in the study, 42 received adalimumab (mean [SD] age, 43.6 [19.6] years; 25 [59.5%] female) and 12 received infliximab (mean [SD] age, 42.7 [20.4] years; 7 [58.3%] male). In the adalimumab group, mean (SD) drug level was 9.72 (6.82) μg/mL, mean (SD) ADA level was 84.2 (172.9) arbitrary units/mL, and ADA frequency was 35.7% (15 of 42 patients). Mean drug level was lower in those with ADAs compared with those without ADAs (mean [SD], 2.8 [2.6] μg/mL vs 13.6 [5.2] μg/mL; difference: 10.8 μg/mL; 95% CI, 8.3-13.2 μg/mL; P <.001). There was a higher mean drug level with concurrent antimetabolite use compared with monotherapy (mean [SD], 11.0 [7.3] μg/mL vs 6.8 [4.5] μg/mL; difference: -4.2 μg/mL; 95% CI, -8.7 to 0.2 μg/mL; P =.06). Multivariable modeling showed that a 1-arbitrary unit increase in ADAs was associated with a -0.02 μg/mL (95% CI, -0.01 to -0.34 μg/mL) difference in mean drug level (P <.001). Favorable clinical response was associated with a threshold drug level above 2.7 μg/mL or an antibody level below 15.2 μg/mL. The mean (SD) drug level in the infliximab group was 27.02 (18.15) μg/mL, and no ADAs were detected. Conclusions and Relevance: In this study, 35.7% of adalimumab-treated patients with NIU had ADAs. The presence of ADAs was associated with lower drug levels, and higher ADA levels were associated with increased risk of TNFi treatment failure. Although limited by the retrospective design, our results suggest that therapeutic drug monitoring may be considered among patients experiencing therapy failure to help exclude ADAs as a potential cause of treatment failure..",
                "correspondence": {
                    "affiliation": {
                        "country": "United States",
                        "address-part": "10 Center Dr, 10/10N248",
                        "postal-code": "20892",
                        "@country": "usa",
                        "city": "Bethesda",
                        "organization": [
                            {"$": "National Eye Institute"},
                            {"$": "National Institutes of Health"}
                        ],
                        "state": "MD",
                        "ce:source-text": "National Eye Institute, National Institutes of Health, 10 Center Dr, 10/10N248, Bethesda, MD 20892"
                    },
                    "person": {
                        "ce:given-name": "Shilpa",
                        "ce:initials": "S.",
                        "ce:degrees": "MD",
                        "ce:surname": "Kodati",
                        "ce:indexed-name": "Kodati S."
                    }
                },
                "citation-info": {
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "sourcetitle-abbrev": "JAMA Ophthalmol.",
                    "website": {"ce:e-address": {
                        "$": "http://archopht.jamanetwork.com/issues.aspx",
                        "@type": "email"
                    }},
                    "@country": "usa",
                    "translated-sourcetitle": {
                        "$": "JAMA Ophthalmology",
                        "@xml:lang": "eng"
                    },
                    "issn": [
                        {
                            "$": "21686173",
                            "@type": "electronic"
                        },
                        {
                            "$": "21686165",
                            "@type": "print"
                        }
                    ],
                    "volisspag": {
                        "voliss": {
                            "@volume": "141",
                            "@issue": "2"
                        },
                        "pagerange": {
                            "@first": "150",
                            "@last": "156"
                        }
                    },
                    "@type": "j",
                    "publicationyear": {"@first": "2023"},
                    "publisher": {"publishername": "American Medical Association"},
                    "sourcetitle": "JAMA Ophthalmology",
                    "@srcid": "21100228531",
                    "publicationdate": {
                        "month": "02",
                        "year": "2023",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "16 February 2023"
                        },
                        "day": "16"
                    }
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "12",
                                    "classification-description": "Ophthalmology"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": "2731"
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "chemicalgroup": {"chemicals": [
                        {
                            "@source": "esbd",
                            "chemical": [
                                {
                                    "cas-registry-number": [
                                        {"$": "331731-18-1"},
                                        {"$": "1446410-95-2"}
                                    ],
                                    "chemical-name": "adalimumab"
                                },
                                {
                                    "cas-registry-number": "446-86-6",
                                    "chemical-name": "azathioprine"
                                },
                                {
                                    "cas-registry-number": "170277-31-3",
                                    "chemical-name": "infliximab"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "15475-56-6"},
                                        {"$": "59-05-2"},
                                        {"$": "7413-34-5"},
                                        {"$": "7532-09-4"},
                                        {"$": "6745-93-3"},
                                        {"$": "51865-79-3"},
                                        {"$": "60388-53-6"}
                                    ],
                                    "chemical-name": "methotrexate"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "116680-01-4"},
                                        {"$": "128794-94-5"},
                                        {"$": "115007-34-6"}
                                    ],
                                    "chemical-name": "mycophenolate mofetil"
                                }
                            ]
                        },
                        {
                            "@source": "nlm",
                            "chemical": [
                                {"chemical-name": "Adalimumab"},
                                {"chemical-name": "Antibodies"},
                                {"chemical-name": "Antimetabolites"},
                                {"chemical-name": "Immunologic Factors"},
                                {"chemical-name": "Immunosuppressive Agents"},
                                {"chemical-name": "Infliximab"},
                                {"chemical-name": "Tumor Necrosis Factor-alpha"}
                            ]
                        }
                    ]}
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2023 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "MEDLINE",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "10",
                    "@timestamp": "BST 06:27:06",
                    "@year": "2023",
                    "@month": "03"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2022994443",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "639843545",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "946248821",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20230180238",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "36547953",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20230518283",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20230709016",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "20239005951513",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85148307020",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85148307020",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "639843545",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "314859899",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.1001/jamaophthalmol.2022.5584"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "26",
                "reference": [
                    {
                        "ref-fulltext": "Jaffe GJ, Dick AD, Brézin AP, Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016; 375 (10): 932-943. doi: 10.1056/NEJMoa1509852 27602665",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1056/NEJMoa1509852",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Adalimumab in patients with active noninfectious uveitis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84986612930",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "375",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "932",
                                    "@last": "943"
                                }
                            },
                            "ref-text": "doi: 27602665",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "G.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Jaffe",
                                    "ce:indexed-name": "Jaffe G.J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.D.",
                                    "@_fa": "true",
                                    "ce:surname": "Dick",
                                    "ce:indexed-name": "Dick A.D."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.P.",
                                    "@_fa": "true",
                                    "ce:surname": "Brézin",
                                    "ce:indexed-name": "Brezin A.P."
                                }
                            ]},
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Jaffe GJ, Dick AD, Brézin AP, Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016; 375 (10): 932-943. doi: 10.1056/NEJMoa1509852 27602665"
                    },
                    {
                        "ref-fulltext": "Nguyen QD, Merrill PT, Jaffe GJ, Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10050): 1183-1192. doi: 10.1016/S0140-6736(16)31339-3 27542302",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1016/S0140-6736(16)31339-3",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84992405281",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "388",
                                    "@issue": "10050"
                                },
                                "pagerange": {
                                    "@first": "1183",
                                    "@last": "1192"
                                }
                            },
                            "ref-text": "doi: 27542302",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "Q.D.",
                                    "@_fa": "true",
                                    "ce:surname": "Nguyen",
                                    "ce:indexed-name": "Nguyen Q.D."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "P.T.",
                                    "@_fa": "true",
                                    "ce:surname": "Merrill",
                                    "ce:indexed-name": "Merrill P.T."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "G.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Jaffe",
                                    "ce:indexed-name": "Jaffe G.J."
                                }
                            ]},
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Nguyen QD, Merrill PT, Jaffe GJ, Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10050): 1183-1192. doi: 10.1016/S0140-6736(16)31339-3 27542302"
                    },
                    {
                        "ref-fulltext": "Vallet H, Seve P, Biard L,; French Uveitis Network. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol. 2016; 68 (6): 1522-1530. doi: 10.1002/art.39667 27015607",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1002/art.39667",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: A multicenter study from the French Uveitis Network"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84971326108",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "68",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "1522",
                                    "@last": "1530"
                                }
                            },
                            "ref-text": "doi: 27015607",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Vallet",
                                        "ce:indexed-name": "Vallet H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Seve",
                                        "ce:indexed-name": "Seve P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Biard",
                                        "ce:indexed-name": "Biard L."
                                    }
                                ],
                                "collaboration": {
                                    "@seq": "1",
                                    "ce:text": "French Uveitis Network",
                                    "ce:indexed-name": "French Uveitis Network"
                                }
                            },
                            "ref-sourcetitle": "Arthritis Rheumatol"
                        },
                        "ce:source-text": "Vallet H, Seve P, Biard L,; French Uveitis Network. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol. 2016; 68 (6): 1522-1530. doi: 10.1002/art.39667 27015607"
                    },
                    {
                        "ref-fulltext": "Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019; 30 (3): 138-150. doi: 10.1097/ICU.0000000000000562 30844945",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1097/ICU.0000000000000562",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Biologics for the treatment of noninfectious uveitis: Current concepts and emerging therapeutics"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85064239656",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "30",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "138",
                                    "@last": "150"
                                }
                            },
                            "ref-text": "doi: 30844945",
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "A.S.",
                                "@_fa": "true",
                                "ce:surname": "Thomas",
                                "ce:indexed-name": "Thomas A.S."
                            }]},
                            "ref-sourcetitle": "Curr Opin Ophthalmol"
                        },
                        "ce:source-text": "Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019; 30 (3): 138-150. doi: 10.1097/ICU.0000000000000562 30844945"
                    },
                    {
                        "ref-fulltext": "Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child. 2019; 104 (3): 246-250. doi: 10.1136/archdischild-2018-315060 30026253",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1136/archdischild-2018-315060",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85050628970",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "104",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "246",
                                    "@last": "250"
                                }
                            },
                            "ref-text": "doi: 30026253",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Skrabl-Baumgartner",
                                    "ce:indexed-name": "Skrabl-Baumgartner A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "G.",
                                    "@_fa": "true",
                                    "ce:surname": "Seidel",
                                    "ce:indexed-name": "Seidel G."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "B.",
                                    "@_fa": "true",
                                    "ce:surname": "Langner-Wegscheider",
                                    "ce:indexed-name": "Langner-Wegscheider B."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Schlagenhauf",
                                    "ce:indexed-name": "Schlagenhauf A."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Jahnel",
                                    "ce:indexed-name": "Jahnel J."
                                }
                            ]},
                            "ref-sourcetitle": "Arch Dis Child"
                        },
                        "ce:source-text": "Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child. 2019; 104 (3): 246-250. doi: 10.1136/archdischild-2018-315060 30026253"
                    },
                    {
                        "ref-fulltext": "Cordero-Coma M, Calleja-Antolín S, Garzo-García I, Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies. Ophthalmology. 2016; 123 (12): 2618-2625. doi: 10.1016/j.ophtha.2016.08.025 27692527",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1016/j.ophtha.2016.08.025",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Adalimumab for treatment of noninfectious uveitis: Immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84996570089",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "123",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "2618",
                                    "@last": "2625"
                                }
                            },
                            "ref-text": "doi: 27692527",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Cordero-Coma",
                                    "ce:indexed-name": "Cordero-Coma M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Calleja-Antolín",
                                    "ce:indexed-name": "Calleja-Antolin S."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "I.",
                                    "@_fa": "true",
                                    "ce:surname": "Garzo-García",
                                    "ce:indexed-name": "Garzo-Garcia I."
                                }
                            ]},
                            "ref-sourcetitle": "Ophthalmology"
                        },
                        "ce:source-text": "Cordero-Coma M, Calleja-Antolín S, Garzo-García I, Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies. Ophthalmology. 2016; 123 (12): 2618-2625. doi: 10.1016/j.ophtha.2016.08.025 27692527"
                    },
                    {
                        "ref-fulltext": "McKay KM, Apostolopoulos N, Chou B, Leveque TK, Van Gelder RN. Anti-adalimumab antibodies in patients with non-infectious ocular inflammatory disease: a case series. Ocul Immunol Inflamm. 2021; 1-5: 1-5. doi: 10.1080/09273948.2021.1936565 34270383",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1080/09273948.2021.1936565",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Anti-adalimumab antibodies in patients with non-infectious ocular inflammatory disease: A case series"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85110901716",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "1-5"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "5"
                                }
                            },
                            "ref-text": "doi: 34270383",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "K.M.",
                                    "@_fa": "true",
                                    "ce:surname": "McKay",
                                    "ce:indexed-name": "McKay K.M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Apostolopoulos",
                                    "ce:indexed-name": "Apostolopoulos N."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "B.",
                                    "@_fa": "true",
                                    "ce:surname": "Chou",
                                    "ce:indexed-name": "Chou B."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "T.K.",
                                    "@_fa": "true",
                                    "ce:surname": "Leveque",
                                    "ce:indexed-name": "Leveque T.K."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "R.N.",
                                    "@_fa": "true",
                                    "ce:surname": "Van Gelder",
                                    "ce:indexed-name": "Van Gelder R.N."
                                }
                            ]},
                            "ref-sourcetitle": "Ocul Immunol Inflamm"
                        },
                        "ce:source-text": "McKay KM, Apostolopoulos N, Chou B, Leveque TK, Van Gelder RN. Anti-adalimumab antibodies in patients with non-infectious ocular inflammatory disease: a case series. Ocul Immunol Inflamm. 2021; 1-5: 1-5. doi: 10.1080/09273948.2021.1936565 34270383"
                    },
                    {
                        "ref-fulltext": "Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-inhibitors. Front Immunol. 2020; 11: 312. doi: 10.3389/fimmu.2020.00312 32174918",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.3389/fimmu.2020.00312",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Immunogenicity of TNF-inhibitors"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85081970219",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "11"},
                                "pagerange": {"@first": "312"}
                            },
                            "ref-text": "doi: 32174918",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Atiqi",
                                    "ce:indexed-name": "Atiqi S."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "F.",
                                    "@_fa": "true",
                                    "ce:surname": "Hooijberg",
                                    "ce:indexed-name": "Hooijberg F."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "F.C.",
                                    "@_fa": "true",
                                    "ce:surname": "Loeff",
                                    "ce:indexed-name": "Loeff F.C."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "T.",
                                    "@_fa": "true",
                                    "ce:surname": "Rispens",
                                    "ce:indexed-name": "Rispens T."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "G.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Wolbink",
                                    "ce:indexed-name": "Wolbink G.J."
                                }
                            ]},
                            "ref-sourcetitle": "Front Immunol"
                        },
                        "ce:source-text": "Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-inhibitors. Front Immunol. 2020; 11: 312. doi: 10.3389/fimmu.2020.00312 32174918"
                    },
                    {
                        "ref-fulltext": "Thomas SS, Borazan N, Barroso N, Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis. BioDrugs. 2015; 29 (4): 241-258. doi: 10.1007/s40259-015-0134-5 26280210",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1007/s40259-015-0134-5",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Comparative immunogenicity of TNF inhibitors: Impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84941425844",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "29",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "241",
                                    "@last": "258"
                                }
                            },
                            "ref-text": "doi: 26280210",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Thomas",
                                    "ce:indexed-name": "Thomas S.S."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Borazan",
                                    "ce:indexed-name": "Borazan N."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Barroso",
                                    "ce:indexed-name": "Barroso N."
                                }
                            ]},
                            "ref-sourcetitle": "BioDrugs"
                        },
                        "ce:source-text": "Thomas SS, Borazan N, Barroso N, Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis. BioDrugs. 2015; 29 (4): 241-258. doi: 10.1007/s40259-015-0134-5 26280210"
                    },
                    {
                        "ref-fulltext": "Brunelli JB, Silva CA, Pasoto SG, Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching. Clin Rheumatol. 2020; 39 (2): 515-521. doi: 10.1007/s10067-019-04798-6 31707543",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1007/s10067-019-04798-6",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Anti-adalimumab antibodies kinetics: An early guide for juvenile idiopathic arthritis (JIA) switching"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85074841643",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "39",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "515",
                                    "@last": "521"
                                }
                            },
                            "ref-text": "doi: 31707543",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Brunelli",
                                    "ce:indexed-name": "Brunelli J.B."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "C.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Silva",
                                    "ce:indexed-name": "Silva C.A."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "S.G.",
                                    "@_fa": "true",
                                    "ce:surname": "Pasoto",
                                    "ce:indexed-name": "Pasoto S.G."
                                }
                            ]},
                            "ref-sourcetitle": "Clin Rheumatol"
                        },
                        "ce:source-text": "Brunelli JB, Silva CA, Pasoto SG, Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching. Clin Rheumatol. 2020; 39 (2): 515-521. doi: 10.1007/s10067-019-04798-6 31707543"
                    },
                    {
                        "ref-fulltext": "Atzeni F, Talotta R, Salaffi F, Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 2013; 12 (7): 703-708. doi: 10.1016/j.autrev.2012.10.021 23207283",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1016/j.autrev.2012.10.021",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Immunogenicity and autoimmunity during anti-TNF therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84877809247",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "12",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "703",
                                    "@last": "708"
                                }
                            },
                            "ref-text": "doi: 23207283",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "F.",
                                    "@_fa": "true",
                                    "ce:surname": "Atzeni",
                                    "ce:indexed-name": "Atzeni F."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "R.",
                                    "@_fa": "true",
                                    "ce:surname": "Talotta",
                                    "ce:indexed-name": "Talotta R."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "F.",
                                    "@_fa": "true",
                                    "ce:surname": "Salaffi",
                                    "ce:indexed-name": "Salaffi F."
                                }
                            ]},
                            "ref-sourcetitle": "Autoimmun Rev"
                        },
                        "ce:source-text": "Atzeni F, Talotta R, Salaffi F, Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 2013; 12 (7): 703-708. doi: 10.1016/j.autrev.2012.10.021 23207283"
                    },
                    {
                        "ref-fulltext": "Sazonovs A, Kennedy NA, Moutsianas L,; PANTS Consortium. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease. Gastroenterology. 2020; 158 (1): 189-199. doi: 10.1053/j.gastro.2019.09.041 31600487",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1053/j.gastro.2019.09.041",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85076249485",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "158",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "189",
                                    "@last": "199"
                                }
                            },
                            "ref-text": "doi: 31600487",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Sazonovs",
                                        "ce:indexed-name": "Sazonovs A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Kennedy",
                                        "ce:indexed-name": "Kennedy N.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Moutsianas",
                                        "ce:indexed-name": "Moutsianas L."
                                    }
                                ],
                                "collaboration": {
                                    "@seq": "1",
                                    "ce:text": "PANTS Consortium",
                                    "ce:indexed-name": "PANTS Consortium"
                                }
                            },
                            "ref-sourcetitle": "Gastroenterology"
                        },
                        "ce:source-text": "Sazonovs A, Kennedy NA, Moutsianas L,; PANTS Consortium. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease. Gastroenterology. 2020; 158 (1): 189-199. doi: 10.1053/j.gastro.2019.09.041 31600487"
                    },
                    {
                        "ref-fulltext": "De Simone C, Amerio P, Amoruso G, Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013; 13 (12): 1673-1682. doi: 10.1517/14712598.2013.848194",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1517/14712598.2013.848194",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Immunogenicity of anti-TNFα therapy in psoriasis: A clinical issue?"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84887917212",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "13",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1673",
                                    "@last": "1682"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "De Simone",
                                    "ce:indexed-name": "De Simone C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "P.",
                                    "@_fa": "true",
                                    "ce:surname": "Amerio",
                                    "ce:indexed-name": "Amerio P."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "G.",
                                    "@_fa": "true",
                                    "ce:surname": "Amoruso",
                                    "ce:indexed-name": "Amoruso G."
                                }
                            ]},
                            "ref-sourcetitle": "Expert Opin Biol Ther"
                        },
                        "ce:source-text": "De Simone C, Amerio P, Amoruso G, Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013; 13 (12): 1673-1682. doi: 10.1517/14712598.2013.848194"
                    },
                    {
                        "ref-fulltext": "Wong U, Cross RK. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. Expert Opin Drug Metab Toxicol. 2017; 13 (10): 1039-1046. doi: 10.1080/17425255.2017.1377180 28876147",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1080/17425255.2017.1377180",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Primary and secondary nonresponse to infliximab: Mechanisms and countermeasures"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85030328834",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "13",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "1039",
                                    "@last": "1046"
                                }
                            },
                            "ref-text": "doi: 28876147",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "U.",
                                    "@_fa": "true",
                                    "ce:surname": "Wong",
                                    "ce:indexed-name": "Wong U."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "R.K.",
                                    "@_fa": "true",
                                    "ce:surname": "Cross",
                                    "ce:indexed-name": "Cross R.K."
                                }
                            ]},
                            "ref-sourcetitle": "Expert Opin Drug Metab Toxicol"
                        },
                        "ce:source-text": "Wong U, Cross RK. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. Expert Opin Drug Metab Toxicol. 2017; 13 (10): 1039-1046. doi: 10.1080/17425255.2017.1377180 28876147"
                    },
                    {
                        "ref-fulltext": "Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012; 91 (4): 635-646. doi: 10.1038/clpt.2011.328 22357456",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1038/clpt.2011.328",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84858793037",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "91",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "635",
                                    "@last": "646"
                                }
                            },
                            "ref-text": "doi: 22357456",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "I.",
                                    "@_fa": "true",
                                    "ce:surname": "Ordás",
                                    "ce:indexed-name": "Ordas I."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "D.R.",
                                    "@_fa": "true",
                                    "ce:surname": "Mould",
                                    "ce:indexed-name": "Mould D.R."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "B.G.",
                                    "@_fa": "true",
                                    "ce:surname": "Feagan",
                                    "ce:indexed-name": "Feagan B.G."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "W.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Sandborn",
                                    "ce:indexed-name": "Sandborn W.J."
                                }
                            ]},
                            "ref-sourcetitle": "Clin Pharmacol Ther"
                        },
                        "ce:source-text": "Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012; 91 (4): 635-646. doi: 10.1038/clpt.2011.328 22357456"
                    },
                    {
                        "ref-fulltext": "Bartelds GM, Wijbrandts CA, Nurmohamed MT, Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007; 66 (7): 921-926. doi: 10.1136/ard.2006.065615 17301106",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2007"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1136/ard.2006.065615",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "34347267600",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "66",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "921",
                                    "@last": "926"
                                }
                            },
                            "ref-text": "doi: 17301106",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "G.M.",
                                    "@_fa": "true",
                                    "ce:surname": "Bartelds",
                                    "ce:indexed-name": "Bartelds G.M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "C.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Wijbrandts",
                                    "ce:indexed-name": "Wijbrandts C.A."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.T.",
                                    "@_fa": "true",
                                    "ce:surname": "Nurmohamed",
                                    "ce:indexed-name": "Nurmohamed M.T."
                                }
                            ]},
                            "ref-sourcetitle": "Ann Rheum Dis"
                        },
                        "ce:source-text": "Bartelds GM, Wijbrandts CA, Nurmohamed MT, Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007; 66 (7): 921-926. doi: 10.1136/ard.2006.065615 17301106"
                    },
                    {
                        "ref-fulltext": "Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013; 72 (12): 1947-1955. doi: 10.1136/annrheumdis-2012-202220 23223420",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1136/annrheumdis-2012-202220",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84887489815",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "72",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1947",
                                    "@last": "1955"
                                }
                            },
                            "ref-text": "doi: 23223420",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Garcês",
                                    "ce:indexed-name": "Garces S."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Demengeot",
                                    "ce:indexed-name": "Demengeot J."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "E.",
                                    "@_fa": "true",
                                    "ce:surname": "Benito-Garcia",
                                    "ce:indexed-name": "Benito-Garcia E."
                                }
                            ]},
                            "ref-sourcetitle": "Ann Rheum Dis"
                        },
                        "ce:source-text": "Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013; 72 (12): 1947-1955. doi: 10.1136/annrheumdis-2012-202220 23223420"
                    },
                    {
                        "ref-fulltext": "Mc Gettigan N, Afridi AS, Harkin G, The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease. Int J Colorectal Dis. 2021; 36 (6): 1231-1241. doi: 10.1007/s00384-021-03855-4 33515082",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1007/s00384-021-03855-4",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85099914958",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "36",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "1231",
                                    "@last": "1241"
                                }
                            },
                            "ref-text": "doi: 33515082",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Mc Gettigan",
                                    "ce:indexed-name": "Mc Gettigan N."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Afridi",
                                    "ce:indexed-name": "Afridi A.S."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "G.",
                                    "@_fa": "true",
                                    "ce:surname": "Harkin",
                                    "ce:indexed-name": "Harkin G."
                                }
                            ]},
                            "ref-sourcetitle": "Int J Colorectal Dis"
                        },
                        "ce:source-text": "Mc Gettigan N, Afridi AS, Harkin G, The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease. Int J Colorectal Dis. 2021; 36 (6): 1231-1241. doi: 10.1007/s00384-021-03855-4 33515082"
                    },
                    {
                        "ref-fulltext": "Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfá E. Immunogenicity of anti-TNF-α agents in autoimmune diseases. Clin Rev Allergy Immunol. 2010; 38 (2-3): 82-89. doi: 10.1007/s12016-009-8140-3 19565360",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1007/s12016-009-8140-3",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Immunogenicity of anti-TNF-α agents in autoimmune diseases"},
                            "refd-itemidlist": {"itemid": {
                                "$": "77953278239",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "2-3"
                                },
                                "pagerange": {
                                    "@first": "82",
                                    "@last": "89"
                                }
                            },
                            "ref-text": "doi: 19565360",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Emi Aikawa",
                                    "ce:indexed-name": "Emi Aikawa N."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.F.",
                                    "@_fa": "true",
                                    "ce:surname": "De Carvalho",
                                    "ce:indexed-name": "De Carvalho J.F."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Artur Almeida Silva",
                                    "ce:indexed-name": "Artur Almeida Silva C."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "E.",
                                    "@_fa": "true",
                                    "ce:surname": "Bonfá",
                                    "ce:indexed-name": "Bonfa E."
                                }
                            ]},
                            "ref-sourcetitle": "Clin Rev Allergy Immunol"
                        },
                        "ce:source-text": "Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfá E. Immunogenicity of anti-TNF-α agents in autoimmune diseases. Clin Rev Allergy Immunol. 2010; 38 (2-3): 82-89. doi: 10.1007/s12016-009-8140-3 19565360"
                    },
                    {
                        "ref-fulltext": "Jabs DA. Immunosuppression for the uveitides. Ophthalmology. 2018; 125 (2): 193-202. doi: 10.1016/j.ophtha.2017.08.007 28942074",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1016/j.ophtha.2017.08.007",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Immunosuppression for the uveitides"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85029630852",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "125",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "193",
                                    "@last": "202"
                                }
                            },
                            "ref-text": "doi: 28942074",
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "D.A.",
                                "@_fa": "true",
                                "ce:surname": "Jabs",
                                "ce:indexed-name": "Jabs D.A."
                            }]},
                            "ref-sourcetitle": "Ophthalmology"
                        },
                        "ce:source-text": "Jabs DA. Immunosuppression for the uveitides. Ophthalmology. 2018; 125 (2): 193-202. doi: 10.1016/j.ophtha.2017.08.007 28942074"
                    },
                    {
                        "ref-fulltext": "Sejournet L, Kerever S, Mathis T, Kodjikian L, Jamilloux Y, Seve P. Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study. Br J Ophthalmol. 2021. 33875451",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: A retrospective study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85148771144",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "33875451",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "L.",
                                    "@_fa": "true",
                                    "ce:surname": "Sejournet",
                                    "ce:indexed-name": "Sejournet L."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Kerever",
                                    "ce:indexed-name": "Kerever S."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "T.",
                                    "@_fa": "true",
                                    "ce:surname": "Mathis",
                                    "ce:indexed-name": "Mathis T."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "L.",
                                    "@_fa": "true",
                                    "ce:surname": "Kodjikian",
                                    "ce:indexed-name": "Kodjikian L."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "Y.",
                                    "@_fa": "true",
                                    "ce:surname": "Jamilloux",
                                    "ce:indexed-name": "Jamilloux Y."
                                },
                                {
                                    "@seq": "6",
                                    "ce:initials": "P.",
                                    "@_fa": "true",
                                    "ce:surname": "Seve",
                                    "ce:indexed-name": "Seve P."
                                }
                            ]},
                            "ref-sourcetitle": "Br J Ophthalmol"
                        },
                        "ce:source-text": "Sejournet L, Kerever S, Mathis T, Kodjikian L, Jamilloux Y, Seve P. Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study. Br J Ophthalmol. 2021. 33875451"
                    },
                    {
                        "ref-fulltext": "Papamichael K, Juncadella A, Wong D, Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease. J Crohns Colitis. 2019; 13 (8): 976-981. doi: 10.1093/ecco-jcc/jjz018 30689771",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1093/ecco-jcc/jjz018",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85068963485",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "13",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "976",
                                    "@last": "981"
                                }
                            },
                            "ref-text": "doi: 30689771",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "K.",
                                    "@_fa": "true",
                                    "ce:surname": "Papamichael",
                                    "ce:indexed-name": "Papamichael K."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Juncadella",
                                    "ce:indexed-name": "Juncadella A."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "D.",
                                    "@_fa": "true",
                                    "ce:surname": "Wong",
                                    "ce:indexed-name": "Wong D."
                                }
                            ]},
                            "ref-sourcetitle": "J Crohns Colitis"
                        },
                        "ce:source-text": "Papamichael K, Juncadella A, Wong D, Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease. J Crohns Colitis. 2019; 13 (8): 976-981. doi: 10.1093/ecco-jcc/jjz018 30689771"
                    },
                    {
                        "ref-fulltext": "Pedersen L, Szecsi PB, Johansen PB, Bjerrum PJ. Evaluation of therapeutic drug monitoring in the clinical management of patients with rheumatic diseases: data from a retrospective single-center cohort study. Biologics. 2020; 14: 115-125. 33162753",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Evaluation of therapeutic drug monitoring in the clinical management of patients with rheumatic diseases: Data from a retrospective single-center cohort study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85094671025",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "14"},
                                "pagerange": {
                                    "@first": "115",
                                    "@last": "125"
                                }
                            },
                            "ref-text": "33162753",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "L.",
                                    "@_fa": "true",
                                    "ce:surname": "Pedersen",
                                    "ce:indexed-name": "Pedersen L."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "P.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Szecsi",
                                    "ce:indexed-name": "Szecsi P.B."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "P.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Johansen",
                                    "ce:indexed-name": "Johansen P.B."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "P.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Bjerrum",
                                    "ce:indexed-name": "Bjerrum P.J."
                                }
                            ]},
                            "ref-sourcetitle": "Biologics"
                        },
                        "ce:source-text": "Pedersen L, Szecsi PB, Johansen PB, Bjerrum PJ. Evaluation of therapeutic drug monitoring in the clinical management of patients with rheumatic diseases: data from a retrospective single-center cohort study. Biologics. 2020; 14: 115-125. 33162753"
                    },
                    {
                        "ref-fulltext": "Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol. 2017; 52 (1): 19-25. doi: 10.1007/s00535-016-1266-1 27665099",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1007/s00535-016-1266-1",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: A systematic review"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84991408411",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "52",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "19",
                                    "@last": "25"
                                }
                            },
                            "ref-text": "doi: 27665099",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "L.",
                                    "@_fa": "true",
                                    "ce:surname": "Martelli",
                                    "ce:indexed-name": "Martelli L."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "P.",
                                    "@_fa": "true",
                                    "ce:surname": "Olivera",
                                    "ce:indexed-name": "Olivera P."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "X.",
                                    "@_fa": "true",
                                    "ce:surname": "Roblin",
                                    "ce:indexed-name": "Roblin X."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Attar",
                                    "ce:indexed-name": "Attar A."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "L.",
                                    "@_fa": "true",
                                    "ce:surname": "Peyrin-Biroulet",
                                    "ce:indexed-name": "Peyrin-Biroulet L."
                                }
                            ]},
                            "ref-sourcetitle": "J Gastroenterol"
                        },
                        "ce:source-text": "Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol. 2017; 52 (1): 19-25. doi: 10.1007/s00535-016-1266-1 27665099"
                    },
                    {
                        "ref-fulltext": "Heron V, Afif W. Update on therapeutic drug monitoring in crohn's disease. Gastroenterol Clin North Am. 2017; 46 (3): 645-659. doi: 10.1016/j.gtc.2017.05.014",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1016/j.gtc.2017.05.014",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Update on therapeutic drug monitoring in crohn's disease"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85028646604",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "46",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "645",
                                    "@last": "659"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "V.",
                                    "@_fa": "true",
                                    "ce:surname": "Heron",
                                    "ce:indexed-name": "Heron V."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "W.",
                                    "@_fa": "true",
                                    "ce:surname": "Afif",
                                    "ce:indexed-name": "Afif W."
                                }
                            ]},
                            "ref-sourcetitle": "Gastroenterol Clin North Am"
                        },
                        "ce:source-text": "Heron V, Afif W. Update on therapeutic drug monitoring in crohn's disease. Gastroenterol Clin North Am. 2017; 46 (3): 645-659. doi: 10.1016/j.gtc.2017.05.014"
                    },
                    {
                        "ref-fulltext": "Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017; 153 (3): 827-834. doi: 10.1053/j.gastro.2017.07.032 28780013",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://dx.doi.org/10.1053/j.gastro.2017.07.032",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85028810296",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "153",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "827",
                                    "@last": "834"
                                }
                            },
                            "ref-text": "doi: 28780013",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Feuerstein",
                                        "ce:indexed-name": "Feuerstein J.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Nguyen",
                                        "ce:indexed-name": "Nguyen G.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kupfer",
                                        "ce:indexed-name": "Kupfer S.S."
                                    },
                                    {
                                        "@seq": "4",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Falck-Ytter",
                                        "ce:indexed-name": "Falck-Ytter Y."
                                    },
                                    {
                                        "@seq": "5",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Singh",
                                        "ce:indexed-name": "Singh S."
                                    }
                                ],
                                "collaboration": {
                                    "@seq": "1",
                                    "ce:text": "American Gastroenterological Association Institute Clinical Guidelines Committee",
                                    "ce:indexed-name": "American Gastroenterological Association Institute Clinical Guidelines Committee"
                                }
                            },
                            "ref-sourcetitle": "Gastroenterology"
                        },
                        "ce:source-text": "Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017; 153 (3): 827-834. doi: 10.1053/j.gastro.2017.07.032 28780013"
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Washington, D.C.",
            "@id": "60025286",
            "affilname": "The George Washington University School of Medicine and Health Sciences",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025286",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bethesda",
            "@id": "60007651",
            "affilname": "National Eye Institute (NEI)",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007651",
            "affiliation-country": "United States"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85148307020",
        "dc:description": "Importance: Tumor necrosis factor inhibitors (TNFis) can induce antidrug antibody (ADA) formation and loss of therapeutic response. However, the utility of ADA testing and the association between ADAs and treatment response in patients with noninfectious uveitis (NIU) is not well understood. Objective: To assess the frequency of ADAs and their association with drug levels and clinical response in patients with NIU treated with adalimumab or infliximab. Design, Setting, and Participants: This retrospective cross-sectional study included patients diagnosed with NIU who received adalimumab or infliximab and underwent testing for serum drug level and ADAs at the National Eye Institute from September 2017 to July 2021. Exposures: Serum drug level testing with reflex testing for ADA levels was performed. Main Outcomes and Measures: The main outcome was the association between drug levels and ADAs, clinical response, and concurrent antimetabolite use in patients treated with TNFis for NIU. Results: Of 54 patients included in the study, 42 received adalimumab (mean [SD] age, 43.6 [19.6] years; 25 [59.5%] female) and 12 received infliximab (mean [SD] age, 42.7 [20.4] years; 7 [58.3%] male). In the adalimumab group, mean (SD) drug level was 9.72 (6.82) μg/mL, mean (SD) ADA level was 84.2 (172.9) arbitrary units/mL, and ADA frequency was 35.7% (15 of 42 patients). Mean drug level was lower in those with ADAs compared with those without ADAs (mean [SD], 2.8 [2.6] μg/mL vs 13.6 [5.2] μg/mL; difference: 10.8 μg/mL; 95% CI, 8.3-13.2 μg/mL; P <.001). There was a higher mean drug level with concurrent antimetabolite use compared with monotherapy (mean [SD], 11.0 [7.3] μg/mL vs 6.8 [4.5] μg/mL; difference: -4.2 μg/mL; 95% CI, -8.7 to 0.2 μg/mL; P =.06). Multivariable modeling showed that a 1-arbitrary unit increase in ADAs was associated with a -0.02 μg/mL (95% CI, -0.01 to -0.34 μg/mL) difference in mean drug level (P <.001). Favorable clinical response was associated with a threshold drug level above 2.7 μg/mL or an antibody level below 15.2 μg/mL. The mean (SD) drug level in the infliximab group was 27.02 (18.15) μg/mL, and no ADAs were detected. Conclusions and Relevance: In this study, 35.7% of adalimumab-treated patients with NIU had ADAs. The presence of ADAs was associated with lower drug levels, and higher ADA levels were associated with increased risk of TNFi treatment failure. Although limited by the retrospective design, our results suggest that therapeutic drug monitoring may be considered among patients experiencing therapy failure to help exclude ADAs as a potential cause of treatment failure..",
        "pubmed-id": "36547953",
        "prism:coverDate": "2023-02-16",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85148307020",
        "dc:creator": {"author": [{
            "ce:given-name": "Sunil",
            "preferred-name": {
                "ce:given-name": "Sunil",
                "ce:initials": "S.",
                "ce:surname": "Bellur",
                "ce:indexed-name": "Bellur S."
            },
            "@seq": "1",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60007651",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007651"
            },
            "ce:degrees": "MD",
            "ce:surname": "Bellur",
            "@auid": "57471254100",
            "author-url": "https://api.elsevier.com/content/author/author_id/57471254100",
            "ce:indexed-name": "Bellur S."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85148307020"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85148307020&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85148307020&origin=inward"
            }
        ],
        "source-id": "21100228531",
        "citedby-count": "1",
        "prism:volume": "141",
        "subtype": "ar",
        "dc:title": "Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients with Noninfectious Uveitis",
        "openaccess": "0",
        "prism:issn": "21686173 21686165",
        "publishercopyright": "© 2023 American Medical Association. All rights reserved.",
        "prism:issueIdentifier": "2",
        "subtypeDescription": "Article",
        "prism:publicationName": "JAMA Ophthalmology",
        "prism:pageRange": "150-156",
        "prism:endingPage": "156",
        "openaccessFlag": "false",
        "prism:doi": "10.1001/jamaophthalmol.2022.5584",
        "prism:startingPage": "150",
        "dc:identifier": "SCOPUS_ID:85148307020",
        "dc:publisher": "American Medical Association"
    },
    "idxterms": {"mainterm": [
        {
            "$": "Adalimumab",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Adult",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Antibodies",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Antimetabolites",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Cross-Sectional Studies",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Drug Monitoring",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Female",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Immunologic Factors",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Immunosuppressive Agents",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Infliximab",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Male",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Retrospective Studies",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Tumor Necrosis Factor-alpha",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Uveitis",
            "@weight": "a",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": null,
    "subject-areas": {"subject-area": [{
        "@_fa": "true",
        "$": "Ophthalmology",
        "@code": "2731",
        "@abbrev": "MEDI"
    }]},
    "authors": {"author": [
        {
            "ce:given-name": "Sunil",
            "preferred-name": {
                "ce:given-name": "Sunil",
                "ce:initials": "S.",
                "ce:surname": "Bellur",
                "ce:indexed-name": "Bellur S."
            },
            "@seq": "1",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60007651",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007651"
            },
            "ce:degrees": "MD",
            "ce:surname": "Bellur",
            "@auid": "57471254100",
            "author-url": "https://api.elsevier.com/content/author/author_id/57471254100",
            "ce:indexed-name": "Bellur S."
        },
        {
            "ce:given-name": "Matthew",
            "preferred-name": {
                "ce:given-name": "Matthew",
                "ce:initials": "M.",
                "ce:surname": "McHarg",
                "ce:indexed-name": "McHarg M."
            },
            "@seq": "2",
            "ce:initials": "M.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60007651",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007651"
                },
                {
                    "@id": "60025286",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025286"
                }
            ],
            "ce:degrees": "BS",
            "ce:surname": "McHarg",
            "@auid": "57216320606",
            "author-url": "https://api.elsevier.com/content/author/author_id/57216320606",
            "ce:indexed-name": "McHarg M."
        },
        {
            "ce:given-name": "Wijak",
            "preferred-name": {
                "ce:given-name": "Wijak",
                "ce:initials": "W.",
                "ce:surname": "Kongwattananon",
                "ce:indexed-name": "Kongwattananon W."
            },
            "@seq": "3",
            "ce:initials": "W.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60007651",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007651"
                },
                {
                    "@id": "60022183",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183"
                }
            ],
            "ce:degrees": "MD",
            "ce:surname": "Kongwattananon",
            "@auid": "57194411173",
            "author-url": "https://api.elsevier.com/content/author/author_id/57194411173",
            "ce:indexed-name": "Kongwattananon W."
        },
        {
            "ce:given-name": "Susan",
            "preferred-name": {
                "ce:given-name": "Susan",
                "ce:initials": "S.",
                "ce:surname": "Vitale",
                "ce:indexed-name": "Vitale S."
            },
            "@seq": "4",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60007651",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007651"
            },
            "ce:degrees": "PhD",
            "ce:surname": "Vitale",
            "@auid": "7102690268",
            "author-url": "https://api.elsevier.com/content/author/author_id/7102690268",
            "ce:indexed-name": "Vitale S."
        },
        {
            "ce:given-name": "H. Nida",
            "preferred-name": {
                "ce:given-name": "H. Nida",
                "ce:initials": "H.N.",
                "ce:surname": "Sen",
                "ce:indexed-name": "Sen H.N."
            },
            "@seq": "5",
            "ce:initials": "H.N.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60007651",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007651"
                },
                {
                    "@id": "60025286",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025286"
                }
            ],
            "ce:degrees": "MD",
            "ce:surname": "Sen",
            "@auid": "7003412064",
            "author-url": "https://api.elsevier.com/content/author/author_id/7003412064",
            "ce:indexed-name": "Sen H.N."
        },
        {
            "ce:given-name": "Shilpa",
            "preferred-name": {
                "ce:given-name": "Shilpa",
                "ce:initials": "S.",
                "ce:surname": "Kodati",
                "ce:indexed-name": "Kodati S."
            },
            "@seq": "6",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60007651",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007651"
            },
            "ce:degrees": "MD",
            "ce:surname": "Kodati",
            "@auid": "57192708531",
            "author-url": "https://api.elsevier.com/content/author/author_id/57192708531",
            "ce:indexed-name": "Kodati S."
        }
    ]}
}}